| (Values in U.S. Thousands) | Sep, 2022 | Jun, 2022 | Mar, 2022 | Dec, 2021 | Sep, 2021 |
| Sales | 1,130 | 0 | 2,550 | 17,500 | 750 |
| Sales Growth | unch | -100.00% | -85.43% | +2,233.33% | unch |
| Net Income | -18,410 | -18,990 | -12,090 | 5,030 | -10,790 |
| Net Income Growth | +3.05% | -57.07% | -340.36% | +146.62% | +31.05% |
F-Star Therapeutics Inc
(FSTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
F-star Therapeutics Inc. is a clinical-stage biopharmaceutical company. It engages in developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. F-star Therapeutics Inc., formerly known as Spring Bank Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.
Fiscal Year End Date: 12/31